London Pharma

London Pharma is a specialty pharmaceutical company that specializes in the reformulation of established drug compounds into sublingual spray formats. The company utilizes its proprietary OroMist delivery platform to enhance the bioavailability and speed of onset for various therapeutics by facilitating absorption through the oral mucosa. By bypassing the gastrointestinal tract and first-pass hepatic metabolism, London Pharma's technology seeks to provide clinical advantages over conventional oral dosage forms. Its development pipeline has featured sublingual versions of ondansetron, sumatriptan, and sildenafil. In 2014, the company was acquired by SUDA Pharmaceuticals (now Arovella Therapeutics), which integrated London Pharma's intellectual property into its mucosal delivery portfolio.